LNP-Delivered mRNA via Inhalation with Ethris' Carsten Rudolph and Thomas Langenickel
Source: Drug Delivery Leader
How can genetic information be carried into lung tissue for the treatment of asthma and potentially other conditions? In this inaugural episode of In Combination, host Tom von Gunden combines the perspectives of two executives from LNP/mRNA (lipidoid nanoparticle / messenger RNA) formulation and delivery platform developer Ethris: CEO Carsten Rudolph and Chief Medical Officer Thomas Langenickel. The conversation illuminates the value to patients of platform approaches to inhalation-delivered treatments.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.
Subscribe to Drug Delivery Leader
X
Subscribe to Drug Delivery Leader
This website uses cookies to ensure you get the best experience on our website. Learn more